SB-203580 is an inhibitor of p38 MAPK that exhibits immunostimulatory, anticancer, and anti-fibrotic activities. In peripheral blood mononuclear cells, SB-203580 increases secretion of IFN-γ. In lung epithelial cells, SB-203580 inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT). Additionally, SB-203580 inhibits proliferation in glioma cells and decreases angiotensin II- and TGF-β1-induced expression of GTGF and fibronectin in other cellular models.
| Cas No. | 152121-47-6 |
|---|---|
| Purity | ≥98% |
| Formula | C21H16FN3OS |
| Formula Wt. | 377.43 |
| IUPAC Name | 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine |
| Synonym | SB203580 |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | S0500 MSDS PDF |
|---|---|
| Info Sheet | S0500 Info Sheet PDF |
Kühnöl C, Herbarth M, Föll J, et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother. 2013 Dec;62(12):1797-809. PMID: 24129764.
Chen HH, Zhou XL, Shi YL, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013 Feb;44(2):93-8. PMID: 23376055.
Morales MG, Vazquez Y, Acuña MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. PMID: 22964022.
